US 8329181
Methods for treating B-cell lymphoma by administering an anti-CD20 antibody
granted A61KA61K2039/505A61P
Quick answer
US patent 8329181 (Methods for treating B-cell lymphoma by administering an anti-CD20 antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/04, A61P11/00